ENGLEWOOD CLIFFS, NJ , Sept. 15, 2022 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (OTCQB: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, announced today that it will effect a 1-for-50 reverse split of its common stock in preparation for the planned listing of the Company’s securities on The Nasdaq Capital…


Previous articleMindMed Announces Compliance with Nasdaq Listing Requirements
Next articleBexson Biomedical Granted USPTO Patent Allowance on Proprietary Formulation Technology, SEVALENT™